Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells.

Authors: Summers, Carolyn M; Hammons, Andrea L; Arora, Jasbir; Zhang, Suhong; Jochems, Jeanine; Blair, Ian A; Whitehead, Alexander S

Published In Eur J Pharmacol, (2014 Jun 5)

Abstract: EA.hy 926 cells grown under low folate conditions adopt a "pro-atherosclerotic" morphology and biochemical phenotype. Pharmacologically relevant doses of the antifolate drug methotrexate (MTX) were applied to EA.hy 926 cells maintained in normal (Hi) and low (Lo) folate culture media. Under both folate conditions, MTX caused inhibition of cell proliferation without significantly compromising metabolic activity. MTX treated Hi cells were depleted of folate derivatives, which were present in altered proportions relative to untreated cells. Transcript profiling using microarrays indicated that MTX treatment modified the transciptome in similar ways for both Hi and Lo cells. Many inflammation-related genes, most prominently those encoding C3 and IL-8, were up-regulated, whereas many genes involved in cell division were down-regulated. The results for C3 and IL-8 were confirmed by quantitative RT-PCR and ELISA. MTX appears to modify the inflammatory potential of EA.hy 926 cells such that its therapeutic properties may, at least under some conditions, be accompanied by the induction of a subset of gene products that promote and/or maintain comorbid pathologies.

PubMed ID: 24657277 Exiting the NIEHS site

MeSH Terms: Antimetabolites, Antineoplastic/diagnostic use; Atherosclerosis/pathology; Bromodeoxyuridine/diagnostic use; Cell Line; Cell Proliferation/drug effects; Cell Survival/drug effects; Folic Acid Antagonists/pharmacology*; Folic Acid Deficiency/pathology; Folic Acid/metabolism*; Gene Expression/drug effects; Humans; Inflammation/pathology*; Methotrexate/pharmacology*; Phenotype

to Top